Stereochemistry | ABSOLUTE |
Molecular Formula | C22H48N12O2 |
Molecular Weight | 512.6957 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1
InChI
InChIKey=HRDUUSCYRPOMSO-ROUUACIJSA-N
InChI=1S/C22H48N12O2/c23-17(5-1-7-31-21(25)26)19(35)29-9-3-11-33-13-15-34(16-14-33)12-4-10-30-20(36)18(24)6-2-8-32-22(27)28/h17-18H,1-16,23-24H2,(H,29,35)(H,30,36)(H4,25,26,31)(H4,27,28,32)/t17-,18-/m0/s1
Ciraparantag (PER-977, aripazine), developed by Perosphere Inc., is a small, synthetic, water-soluble, cationic molecule and can reverse the anticoagulation mediated by unfractionated heparin, low-molecular-weight heparin, factor Xa and factor IIa inhibitors, and fondaparinux. It has the potential to be a universal antidote, inhibiting nearly all anticoagulants except vitamin K antagonists and argatroban. In April 2015, ciraparantag received FDA fast-track designation as an investigational anticoagulant reversal agent. Phase I/II
trials are currently underway to evaluate the safety and efficacy
of PER977 in reversing anticoagulation of edoxaban,
LMWH, and UFH.2.
Originator
Approval Year
Cmax
T1/2
Sourcing
PubMed
Patents
Sample Use Guides
Single intravenous doses of Ciraparantag (100–300 mg) that completelyreversed anticoagulation associated with a single doseof edoxaban (60 mg) in healthy volunteers within 10 minutesand maintained reversal over 24 hours with no rebound andno need for infusions or repeat administration.
Route of Administration:
Intravenous